Trial results for a combination therapy involving Nivolumab and a PD-L1/IDO peptide vaccine in patients with metastatic melanoma were posted on ClinicalTrials.gov on 2025-02-20. The study found that the combination arm achieved a median progression-free survival of 25.5 months.
Background
Nivolumab is a programmed death 1 (PD-1) regulatory antibody, a standard immunotherapeutic treatment for various cancers. Combination therapy is an increasingly common approach in oncological diseases, aiming to enhance treatment efficacy. This trial investigated combining Nivolumab with a peptide vaccine designed to target programmed death ligand 1 (PD-L1) and Indoleamine 2,3-dioxygenase (IDO) in patients with metastatic melanoma.
Trial design
This completed Phase 1/Phase 2 trial (NCT03047928) enrolled 48 participants with metastatic melanoma. The study investigated combination therapy with Nivolumab and a PD-L1/IDO peptide vaccine. The trial tested the combination of Nivolumab, administered every second week, with the PD-L1/IDO peptide vaccine, also given every second week for the first six weeks. Results were reported across three groups: Arm A, Arm B, and Arm C.
Key results
Key outcomes from the trial included objective response rate, progression-free survival, overall survival, and the number of participants experiencing adverse events.
- Objective Response Rate:
- Arm A: 24 participants
- Arm B: 0 participants
- Arm C: 2 participants
- Progression Free Survival (median):
- Arm A: 25.5 months
- Arm B: 2.4 months
- Arm C: Data not available ("NA")
- Overall Survival (median):
- Arm A: Data not available ("NA")
- Arm B: 16.7 months
- Arm C: Data not available ("NA")
- Number of Participants with Adverse Events:
- Arm A: 30 participants
- Arm B: 10 participants
- Arm C: 4 participants
What this means
The results suggest that the combination of Nivolumab and the PD-L1/IDO peptide vaccine (Arm A) demonstrated a notable clinical benefit in patients with metastatic melanoma, particularly in terms of progression-free survival and objective response rate. The median progression-free survival of 25.5 months in Arm A is substantially higher than the 2.4 months observed in Arm B. While Arm A also reported the highest number of participants with adverse events (30 participants), the efficacy signals, especially the objective response rate of 24 participants, indicate a promising therapeutic approach. Further research would be needed to fully understand the risk-benefit profile and optimal patient populations for this combination.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for study NCT03047928, titled "Combination Therapy With Nivolumab and PD-L1/IDO Peptide Vaccine to Patients With Metastatic Melanoma," were posted on 2025-02-20 on clinicaltrials.gov.